Blue Owl Capital Holdings LP Sells 20,000 Shares of Disc Medicine, Inc. $IRON

Key Points

• Blue Owl Capital cut its stake in Disc Medicine by 16.4%, selling 20,000 shares and leaving it with 102,260 shares (about 0.29% of the company), valued at roughly $6.76 million and its 17th-largest holding.
• Insiders have been selling heavily: William Jacob Savage sold 7,378 shares and CFO Jean M. Franchi sold 7,081 shares, and insiders disposed of a total of 292,492 shares worth $25,423,925 over the past 90 days (insiders now own 3.64%).
• Analysts have trimmed price targets but the stock retains a consensus "Moderate Buy" rating with an average target of $104.80, while shares recently traded near $61 and have a 52-week range of $30.82–$99.50.

Blue Owl Capital Holdings LP lowered its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 16.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 102,260 shares of the company's stock after selling 20,000 shares during the period. Disc Medicine comprises about 2.1% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 17th biggest holding. Blue Owl Capital Holdings LP owned approximately 0.29% of Disc Medicine worth $6,757,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new position in shares of Disc Medicine during the third quarter valued at about $38,000. Avanza Fonder AB boosted its holdings in shares of Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company's stock worth $110,000 after purchasing an additional 585 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company's stock worth $133,000 after purchasing an additional 206 shares during the last quarter. Bryce Point Capital LLC bought a new stake in shares of Disc Medicine in the third quarter worth about $259,000. Finally, Tower Research Capital LLC TRC increased its holdings in Disc Medicine by 383.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company's stock valued at $211,000 after purchasing an additional 3,152 shares during the period. Institutional investors own 83.70% of the company's stock.

Insider Activity at Disc Medicine

In other news, insider William Jacob Savage sold 7,378 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $65.88, for a total transaction of $486,062.64. Following the sale, the insider owned 85,211 shares in the company, valued at approximately $5,613,700.68. The trade was a 7.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jean M. Franchi sold 7,081 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total transaction of $463,593.07. Following the completion of the sale, the chief financial officer directly owned 71,343 shares in the company, valued at $4,670,826.21. This represents a 9.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 292,492 shares of company stock valued at $25,423,925 over the last ninety days. Insiders own 3.64% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on IRON. Stifel Nicolaus dropped their price objective on Disc Medicine from $125.00 to $110.00 and set a "buy" rating for the company in a report on Tuesday, February 17th. Cantor Fitzgerald reduced their target price on Disc Medicine from $153.00 to $125.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a report on Wednesday, January 21st. BMO Capital Markets dropped their price target on Disc Medicine from $120.00 to $100.00 and set an "outperform" rating for the company in a research note on Tuesday, February 17th. Finally, Morgan Stanley set a $75.00 price target on shares of Disc Medicine in a report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $104.80.

Disc Medicine Stock Performance

Shares of IRON opened at $61.18 on Friday. The company has a 50-day simple moving average of $72.69 and a two-hundred day simple moving average of $75.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 23.45. The firm has a market capitalization of $2.31 billion, a PE ratio of -10.21 and a beta of 0.87. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, topping analysts' consensus estimates of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts' expectations of $0.15 million. On average, analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.